Last reviewed · How we verify

NCT05495932: CESAM

Mepolizumab Pharmacokinetics Among Patients With Severe Asthma

Completed NA Last updated 30 September 2025
What this trial tests

NA trial testing blood sample in Asthma in 50 participants. Completed in 20 December 2024.

Timeline
15 November 2022
Primary endpoint
20 December 2024
20 December 2024

Quick facts

Lead sponsorUniversity Hospital, Montpellier
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment50
Start date15 November 2022
Primary completion20 December 2024
Estimated completion20 December 2024
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Asthma is a chronic disease characterized by inflammation and obstruction of the airways. Identification of the mechanisms of action of corticosteroids has made it possible to define the type 2 inflammation present in nearly 80% of patients with asthma. Monoclonal antibodies (MAb) in severe asthma target type-2 inflammation. Mepolizumab is a humanized IgG1 (immunoglobulin gamma-1) kappa subclass monoclonal antibody directed specifically against interleukin 5 (IL-5). It acts specifically on eosinophil homeostasis, with IL-5 being a key interleukin in eosinophil maturation. The investigators propose to measure the concentrations of mepolizumab in the serum of asthmatic patients treated with this mAb. The investigators hypothesize that the individual pharmacokinetics (PK) of mepolizumab may differ between clinical responders and non-responders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of blood sample

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing